Literature DB >> 23547804

Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease.

Simon Winther, Jeppe Hagstrup Christensen, Allan Flyvbjerg, Erik Berg Schmidt, Kaj Anker Jørgensen, Hanne Skou-Jørgensen, My Svensson.   

Abstract

BACKGROUND: Patients treated with hemodialysis (HD) have an increased mortality, mainly caused by cardiovascular disease (CVD). Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of the vascular calcification process. Previous studies have demonstrated that OPG is a prognostic marker of mortality. The aim of this study was to investigate if OPG was a prognostic marker of all-cause mortality in high-risk patients with end-stage renal disease and CVD.
METHODS: We prospectively followed 206 HD patients with CVD. OPG was measured at baseline and the patients were followed for 2 years or until reaching the primary endpoint, i.e., all-cause mortality.
RESULTS: All-cause mortality during follow-up was 44% (90/206). High OPG was associated with increased mortality, using the first tertile as reference, with an unadjusted HR of 1.70 (CI 1.00 - 2.88) for the second tertile and HR of 1.63 (CI 0.96 - 2.78) for the third tertile. In a multivariate Cox-regression analysis age, CRP and OPG in both the second and third tertile were significantly associated with increased mortality In the unadjusted survival analysis, a test for trend of OPG yielded a p-value of 0.08; in the adjusted analyses, the p-value for trend was 0.03.
CONCLUSIONS: In a high-risk population of hemodialysis patients with previously documented cardiovascular disease, a high level of OPG was an independent risk marker of all-cause mortality.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23547804     DOI: 10.5414/CN107803

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

1.  Calcification Biomarkers, Subclinical Vascular Disease, and Mortality Among Multiethnic Dialysis Patients.

Authors:  Jessica Fitzpatrick; Esther D Kim; Stephen M Sozio; Bernard G Jaar; Michelle M Estrella; Jose M Monroy-Trujillo; Rulan S Parekh
Journal:  Kidney Int Rep       Date:  2020-08-06

2.  Osteoprotegerin Is a Better Predictor for Cardiovascular and All-Cause Mortality than Vascular Calcifications in a Multicenter Cohort of Patients on Peritoneal Dialysis.

Authors:  Marcela Ávila; Ma Del Carmen Prado; Renata Romero; Ricardo Córdova; Ma Del Carmen Rigo; Miguel Trejo; Carmen Mora; Ramón Paniagua
Journal:  Biomolecules       Date:  2022-04-08

3.  Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.

Authors:  M M Nascimento; S Y Hayashi; M C Riella; B Lindholm
Journal:  Braz J Med Biol Res       Date:  2014-08-22       Impact factor: 2.590

4.  Circulating Osteoprotegerin Levels Independently Predict All-cause Mortality in Patients with Chronic Kidney Disease: a Meta-analysis.

Authors:  Qing-Xiu Huang; Jian-Bo Li; Xiao-Wen Huang; Lan-Ping Jiang; Lin Huang; Hai-Wen An; Wen-Qin Yang; Jie Pang; Yan-Lin Li; Feng-Xian Huang
Journal:  Int J Med Sci       Date:  2019-09-07       Impact factor: 3.738

5.  Novel Biomarkers Detected by Proteomics Predict Death and Cardiovascular Events in Hemodialysis Patients.

Authors:  Ping-Hsun Wu; Rie Io Glerup; My Hanna Sofia Svensson; Niclas Eriksson; Jeppe Hagstrup Christensen; Philip de Laval; Inga Soveri; Magnus Westerlund; Torbjörn Linde; Östen Ljunggren; Bengt Fellström
Journal:  Biomedicines       Date:  2022-03-22

6.  Omega 3 fatty acids effect on the vascular calcification biomarkers fetuin A and osteoprotegerin in hemodialysis patients.

Authors:  Rehab H Werida; Sohaila Abou-Madawy; Mohamed Abdelsalam; Maged W Helmy
Journal:  Clin Exp Med       Date:  2021-07-20       Impact factor: 3.984

7.  Transglutaminase-2 Is Involved in Expression of Osteoprotegerin in MG-63 Osteosarcoma Cells.

Authors:  Hye Ja Lee; Chang Hoon Lee
Journal:  Biomol Ther (Seoul)       Date:  2013-05-30       Impact factor: 4.634

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.